Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amlodipine
Drug ID BADD_D00121
Description Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers [A175327]. Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321]. The option for single daily dosing of amlodipine is an attractive feature of this drug [FDA label].
Indications and Usage For the treatment of hypertension and chronic stable angina.
Marketing Status Prescription; Discontinued
ATC Code C08CA01
DrugBank ID DB00381
KEGG ID D07450
MeSH ID D017311
PubChem ID 2162
TTD Drug ID D08JIV
NDC Product Code 52652-5001; 46287-035
Synonyms Amlodipine | Amlodipine, (+-)-Isomer | Amlodipine Besylate | Amlodipine, (+-)-Isomer, Maleate (1:1) | Amlodipine, (S)-Isomer, Maleate (1:1) | Amlodis | Astudal | Norvasc | Istin | Amlor | Amlodipine Maleate | Amlodipine Maleate (1:1) | Amlodipine, (R)-Isomer
Chemical Information
Molecular Formula C20H25ClN2O5
CAS Registry Number 88150-42-9
SMILES CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood pressure diastolic decreased13.14.03.0030.000046%Not Available
Blood pressure fluctuation24.06.01.0020.000031%Not Available
Blood pressure increased13.14.03.0050.000399%Not Available
Blood pressure systolic increased13.14.03.0060.000031%Not Available
Blood urea increased13.13.01.0060.000077%Not Available
Blood uric acid increased13.02.04.0010.000031%Not Available
Bradycardia02.03.02.0020.000353%Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Burning sensation08.01.09.029; 17.02.06.001--Not Available
C-reactive protein increased13.09.01.0070.000061%Not Available
Cardiac arrest02.03.04.0010.000060%
Cardiac failure02.05.01.0010.000056%
Cardiac failure congestive02.05.01.002--Not Available
Cardio-respiratory arrest22.02.06.007; 02.03.04.0020.000020%Not Available
Cardiogenic shock24.06.02.006; 02.05.01.0030.000077%Not Available
Carotid artery thrombosis24.01.04.007; 17.08.01.0250.000031%Not Available
Cataract06.06.01.0010.000046%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000048%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.000215%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000138%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.000322%Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.02.05.0010.000031%Not Available
Cholestasis09.01.01.001--Not Available
Chondrocalcinosis pyrophosphate15.01.06.003; 14.04.01.0100.000031%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Coagulopathy01.01.02.001--Not Available
Cold sweat23.02.03.002; 08.01.03.024--Not Available
Colitis ischaemic24.04.08.012; 07.08.01.0040.000046%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 17 Pages